Abstract
Fifty-five patients with metastatic renal cell carcinoma (RCC) were treated on a multicenter, single-arm Phase II trial. Patients received single-agent Cetuximab (C225) administered by intravenous infusion at a loading dose of 400 or 500 mg/m2 followed by weekly maintenance doses at 250 mg/m2. None of the patients treated with C225 achieved either a complete or partial response. The median time to progression was 57 days. The most frequently reported grade 3 or 4 toxicity treatment-related adverse events were acne (17%) and rash or dry skin (4%). The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.
Similar content being viewed by others
References
Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 163: 408–417, 2000
Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3: 2703–2707, 1997
Lager DJ, Slagel DD, Palechek PL: The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod Pathol 7: 544–548, 1994
Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin, DJ: Mouse human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4: 2957–2966, 1998
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289–296, 2002
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Motzer, R.J., Amato, R., Todd, M. et al. Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma. Invest New Drugs 21, 99–101 (2003). https://doi.org/10.1023/A:1022928612511
Issue Date:
DOI: https://doi.org/10.1023/A:1022928612511